Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: A prospective and single arm study (DANCE study)

A phase II study of the PI3K inhibitor copanlisib in combination with the antiCD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: Treatment rationale and protocol design of the COUP-1 trial

8 p | 11 | 3

A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: Rationale and study protocol design for the LOGIK1702 study

6 p | 7 | 2

Rationale and design of LUX-Head & Neck 1: A randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy

9 p | 11 | 2

Breast ductal lavage for biomarker assessment in high risk women: Rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo

10 p | 6 | 1

Rationale and design of extended cancer education for longer term survivors (EXCELS): A randomized control trial of ‘high touch’ vs. ‘high tech’ cancer survivorship self-management tools in primary care

11 p | 14 | 1

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: Treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)

6 p | 12 | 1

Phase II, multi-center, open-label, singlearm clinical trial evaluating the efficacy and safety of Mycophenolate Mofetil in patients with high-grade locally advanced or metastatic osteosarcoma (ESMMO): Rationale and design of the ESMMO trial

10 p | 13 | 0